Alzamend neuro submits ind application for phase i/iia trial for an immunotherapy (alzn002) to treat mild to moderate dementia of the alzheimer's type

Atlanta--(business wire)---- $acad #al002--alzamend neuro submits ind application for phase i/iia trial for an immunotherapy (alzn002) to treat mild to moderate dementia of the alzheimer's type
ACAD Ratings Summary
ACAD Quant Ranking